breast cancer res treat

Jaeyun Jung, Hyang Sook Seol, Suhwan Chang. Res Treat. 2018;50(1):1-10. Published online September 13, 2017 DOI: 275, No Association of Positive Superficial and/or Deep Margins with Local Recurrence in Invasive Cancer Treated with Breast-Conserving Surgery. Breast Cancer Research and Treatment. Breast Research and Treatment is a scientific journal focused on the treatment of and investigations in breast cancer. It is targeted towards a wide audience of clinical researchers, epidemiologists, immunologists, or cell biologists interested in breast cancer. The results of epidemiologic studies of the association between cigarette smoking and breast cancer risk have been inconsistent. In spite of the inconsistency, several recent analyses have suggested an increased risk of breast cancer among women who smoked cigarettes for a long period and/or who started smoking  Key words: advances breast cancer, aromatase inhibitor, endocrine therapy, fulvestrant, postmenopausal, SAKK. Trial 21/00 Breast Cancer Res. Treat 2005; 93 (Suppl 1): S11–S18. 8. Hu XF, Veroni M, De Luise M et al. Circumvention of tamoxifen resistance by the pure anti-estrogen ICI 182,780. Int J Cancer 1993; 55:  Breast Research and Treatment provides the surgeon, radiotherapist, medical oncologist, endocrinologist, epidemiologist, immunologist or cell biologist investigating problems in cancer a single forum for communication. None of these journals provides a focus on the unique problems of breast cancer.

Breast Cancer Research and Treatment | Read articles with impact on ResearchGate, the professional network for scientists. PubMed Journal articles for Breast Cancer Res Treat were found in PRIME PubMed. Download Prime PubMed App to iPhone or iPad. Technology in Research & Treatment (TCRT) (2016 Impact Factor 2.204*) is a broad-spectrum, open access, peer-reviewed journal provides researchers an Breast Res Treat 166 (1), 1-13. 2017 Jul 10. Currently available data supporting adjuvant ovarian function suppression for resected breast in premenopausal women in addition to standard chemotherapy and tamoxifen are not persuasive, even though an ASCO guideline supports them. Available information  Results 1 - 10 of 3116 - Source: Breast Cancer Res Treat | Posted 2 weeks ago. Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the therapy expert group (BCTEG); Abraham J, Caldera H et al.; Cancer Research and Treatment (Jan 2018)  Abbreviation: Breast Res. Treat. Published by: Holtzbrinck Springer Nature Publishing Group. Publisher Location: Dordrecht, Netherlands. Journal Website: Range of citations in the SafetyLit database: 2016; 159(2) -- 2016; 159(2). Publication Date Range: 1981 --. Number of  15 Feb 2014 - Exploring novel approaches to treatment of these subtypes is critical because less than 30% of women with metastatic breast cancer survive five years Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes.

Breast Cancer Res Treat 2008;109:123–39. No mutations in the BACH1 gene in BRCA1 and BRCA2 negative breast-cancer families linked to 17q22. Int J Cancer. 2002;98(4):638–9. McInerney NM, et al. Evaluation of variants in the CHEK2, BRIP1 and PALB2 genes in an Irish breast cancer cohort. Breast Cancer Res Treat. 2010;121(1):203–10. Kuusisto KM, et al. Breast Cancer Research is the leading journal in the breast cancer field. The journal publishes research and reviews of exceptional interest covering all areas of biology and medicine relevant to breast cancer, with a special emphasis on the genetic, biochemical and cellular basis of breast cancer. As an international  T. Tominaga, O. Abe, M. Izuo and Y. Nomura, A phase I study of toremifene, Breast Res Treat 16(Suppl) (1990), S27–29. J.T. Hamm, D.C. Tormey, PC. Kohler, D. Haller, M. Green and I. Shemano, Phase I study of toremifene in patients with advanced J. Clin Oncol 9 (1991), 2036–2041. R. Valavaara, Phase II  18 Dec 2009 - C. Denkert 4 J. Budczies. Charité Universitaetsmedizin, Berlin, Germany. Z. Szallasi. Children's Hospital Informatics Program at the Harvard-MIT. Division of Health Sciences and Technology (CHIP@HST),. Harvard Medical School, Boston, MA, USA. 123. Breast Cancer Res Treat (2010) 123:725–731. of any new lesion.

Stable disease (SD) was classified as neither sufficient shrinkage to qualify for a PR nor increase to qualify for PD lasting ≥6 months. CB rate was defined as the sum of all patients experi- encing CR, PR or SD ≥6 months. Due to variation in the. 60. Breast Cancer Res Treat (2008) 109:59–65. 123  Erratum: Enhanced serine production by bone metastatic breast cancer cells stimulates osteoclastogenesis Cancer Res Treat DOI 10.1007/s10549-010- 0848-5). Sirkku Pollari, Sanna Maria Käkönen, Henrik Edgren, Maija Wolf, Pekka Kohonen, Henri Sara, Theresa Guise, Matthias Nees, Olli Kallioniemi. 9 Dec 2010 - Breast Cancer Res Treat. 2011 Nov;130(1):29-40. Valabrega G, Capellero S, Cavalloni G, Zaccarello G, Petrelli A, Migliardi G, Milani A, Peraldo-Neia C, Gammaitoni L, Sapino A, Pecchioni C, Moggio A, Giordano S, Aglietta M, Montemurro F. 9Polyzos, A, Malamos, N, Boukovinas, I et al. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). Cancer Res Treat. 2010; 119: 95–104. Clinical and pathologic characteristics of BRCA-positive and BRCA-negative male breast cancer patients: results from a collaborative multicenter study in Italy. Breast Res Treat. 2012;134(1):411–8. Ding YC, Steele L, Kuan CJ, Greilac S, Neuhausen SL.

Mutations in BRCA2 and PALB2 in male breast cancer cases  The MCF7/164R-5 Cell line is a cancer cell line resistant to fulvestrant.Treatment with the A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells. Europe PMC ID: 25362855. View. Sonne-Hansen et al. 2010. Breast Res Treat. Breast Res Treat. 2004 Feb;83(3):221-31. Growth inhibitory activity of extracts and purified components of black cohosh on human cancer cells. Einbond LS, Shimizu M, Xiao D, Nuntanakorn P, Lim JT, Suzui M, Seter C, Pertel T, Kennelly EJ, Kronenberg F, Weinstein IB. Herbert Irvign Comperhensive Cancer  Biol Ther 2004;3:772–5. Baselga J, Roche H, Fumoleau P, et al. Treatment of postmenopausal women with locally advanced or metastatic breast cancer with letrozole alone or in combination with temsirolimus: a randomized, 3-arm, phase 2 study. Breast Cancer Res Treat 2005;94(Suppl 1):Abstract 1068. Baselga  Records of female breast cancer patients were selected from a clinical cancer registry and separated into three cohorts according to HER2-status (human epidermal growth factor receptor 2) and treatment with or without Trastuzumab (a humanized monoclonal antibody). Propensity score matching was used to balance the  Breast Research and Treatment provides the surgeon, radiotherapist, medical oncologist, endocrinologist, epidemiologist, immunologist or cell biologist investigating problems in breast cancer a single forum for communication.

None of these journals provides a focus on the unique problems of breast cancer. 2018/01. Type: Published Erratum DOI: 10.1007/s10549-017-4505-0 The Digital Object Identifier (DOI) System enables identification of digital entities. This corrects "Utilization of bioimpedance spectroscopy in the prevention of chronic breast cancer-related lymphedema." Breast Cancer Res Treat. 2017 Dec;166(3):809-815  26 Oct 2017 - Question Are 70-gene signature assay findings associated with physicians' treatment decisions for patients with intermediate findings on the 21-gene assay? Findings In this study of 840 patients with early breast 282 physicians (33.6%) changed their treatment decision after receiving the 70-gene  ER+/HER2- breast cancer: low TIL score after chemotherapy predicts better RFS. Cancer Res Treat; from Miriam Davis, PhD; Clinical Essentials; 30 Nov 2017. Access to the full content of this site is available only to registered healthcare professionals. > Access to the full content of this site is available only to  3 May 2015 - Abstract. To determine whether CYP19A1 polymorphisms are associated with abnormal activity of aromatase and with musculoskeletal and bone side effects of aromatase inhibitors. DNA was isolated from tumor specimens of 4861 postmenopausal women with hormone receptor- positive breast cancer .

Your name (required)
Your e-mail (required)